Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of “Buy” from Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has received an average rating of “Buy” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $74.86.

JSPR has been the subject of a number of recent research reports. Royal Bank of Canada reduced their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research note on Wednesday, August 14th. Evercore ISI restated an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a report on Thursday, October 24th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a report on Tuesday, October 15th.

Jasper Therapeutics Price Performance

Jasper Therapeutics stock opened at $20.02 on Tuesday. The firm has a 50-day moving average of $20.26 and a 200-day moving average of $20.89. Jasper Therapeutics has a one year low of $4.00 and a one year high of $31.01. The company has a market cap of $302.30 million, a price-to-earnings ratio of -4.22 and a beta of 2.19.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds have recently modified their holdings of JSPR. Braidwell LP bought a new stake in Jasper Therapeutics in the third quarter valued at $9,091,000. Ally Bridge Group NY LLC grew its position in Jasper Therapeutics by 82.7% in the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares in the last quarter. StemPoint Capital LP bought a new stake in Jasper Therapeutics in the 1st quarter worth about $3,794,000. Ikarian Capital LLC purchased a new position in Jasper Therapeutics in the first quarter valued at about $3,088,000. Finally, Russell Investments Group Ltd. purchased a new position in Jasper Therapeutics in the first quarter valued at about $2,343,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.